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Cisplatin is a chemotherapy agent commonly used in the treatment of many cancers, including 
ovarian, testicular and lung cancer. It cross-links the two strands of the DNA helix, which inhibits 
DNA replication and transcription, and eventually induces cell death or senescence. In many cases, 
however, the cancer develops resistance to cisplatin, and there is no known treatment for these 
resistant tumors. 
However, through advancements in an understanding of the genetic basis of Fanconi Anemia, one 
mechanism of cisplatin resistance in cancer cells is becoming clearer. Fanconi Anemia is a rare 
genetic disorder caused by defects in a DNA damage response pathway (the so-named Fanconi 
Anemia (FA) pathway) that coordinates the sensing, signaling and repair of DNA cross-links through 
multiple DNA repair mechanisms, including homologous recombination (HR). As a result, cells from 
FA patients exhibit hypersensitivity to DNA cross-linking agents; whereas cancer cells that have an 
intact FA pathway utilize it to counter the damaging effects of such agents. 
Postdoctoral fellow Dr. Celine Jacquemont in the Taniguchi Lab of the Human Biology and Public 
Health Sciences divisions, Dr. Julian Simon of the HB and Clinical Research divisions, and external 
colleagues have thus initiated a research effort to find small molecule drugs that inhibit the FA 
pathway in order to treat cisplatin-resistant cancer. Toward this end, they have developed an assay 
that measures FA pathway activation by quantifying nuclear FANCD2 foci formation, as this FA 
protein’s accumulation at the site(s) of DNA damage is required for DNA repair and cell survival. The 
authors initially screened over 16,000 compounds for inhibitors that significantly reduced FANCD2 
foci formation following radiation treatment. Twenty-six compounds were identified (some with a sub-
micromolar IC50), including four compounds previously found by this group in a smaller scale 
screening. Twenty-three of these compounds also significantly decreased HR as evaluated in an HR 
reporter assay. 
Because the integrity of the FA and HR pathways is required for survival to cisplatin treatment, the 
authors then evaluated the 26 candidate compounds for their ability to enhance the cytotoxic effects 
of cisplatin in an FA pathway-deficient ovarian cancer cell line, where the FA gene (FANCF) is 
epigenetically silenced, versus an isogenic form of the same cell line in which the pathway is 
restored by over-expression of FANCF. 
Fourteen of the 26 compounds synergized with cisplatin to reduce cell survival of ovarian cancer 
cells. The majority showed a stronger synergism with cisplatin in FA-proficient than in the FA-
deficient cells, suggesting that their FA pathway inhibitory activity contributes to the cisplatin 
sensitization. Some of the candidates identified through this screen are already in clinical trials with 
cisplatin for the treatment of ovarian cancer and other cancers (e.g., bortezomib). In addition, one 
new compound (Chembridge compound 5373662) selectively synergized with cisplatin and radiation  
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in FA-proficient cells and is undergoing further investigation, both for its clinical utility and its 
mechanism of action. Undoubtedly, results forthcoming from these studies will inform the 
prospective power of this screening method for identifying compounds that sensitize cancer cells to 
cisplatin. 
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Isobologram analyses of synergistic cytotoxicity when candidate FA pathway 
inhibitors are administered with cisplatin to ovarian cancer cells with a 
deficient FA pathway (2008) or an intact FA pathway (2008 + FA). LD50 is 
50% killing dose. Data points falling below the diagonal line indicate 
synergism, data points on the diagonal indicate additive effect, and data 
points above the line indicate antagonism. Chloroquine has been shown to 
enhance the effect of radiation and other chemotherapies; Chembridge 
compound 5373662 is a lead small molecule identified in this study to 
enhance cisplatin and radiation-induced cytotoxicity through selective 
inhibition of the FA pathway; bortezomib is currently undergoing evaluation as 
a combination therapy to treat ovarian cancer with cisplatin. 
 
